Anti-tumour necrosis factor alpha (Infliximab) in the treatment of severe ulcerative colitis: Result of an open study on 13 patients

Digestive and Liver Disease

Volumn 34, Issue 9, 2002, Pages 626-630

  Kohn, A ^a   Prantera, C ^a   Pera, A ^a   Cosintino, R ^a   Sostegni, R ^a,b   Daperno, M ^a,b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

Infliximab; Monoclonal antibody; Severe colitis; Steroid refractory; Tumour necrosis factor alpha; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; RASH; REMISSION; SCHOOL CHILD; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0036743233     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80204-3     Document Type: Article

References (28)

1. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor α, interleukin-1β and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
2. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, et al. Tumor necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet 1999;353:459-61.
3. Schurmann G, Betzler M, Post S, Herfarth C, Meuer S. Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations. Digestion 1992;51:51-9.
4. Murch SH, Lamkin VA, Savage MO, Walker Smith JA, Mac Donald TT. Serum concentrations of tumour necrosis alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
5. Reimund J-M, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16:144-50.
6. Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, et al. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992;14:451-61.
7. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumor necrosis factor alpha. Gut 1997;40:628-33.
8. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
9. Present DH, Rutgeerts T, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
10. D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-34.
11. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CD, et al. A randomized double blind, placebo-controlled, multi-center trial of engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000;118:A655
12. Co MS, Queen C. Humanized antibodies for therapy. Nature 1991;351:501-2.
13. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117:761-9.
14. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
15. Sands BE, Tremaine WJ, Sandbom WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8.
16. Kohn A, Cosintino R, Falasco G, Prantera C. Infliximab therapy for severe ulcerative colitis refractory to steroid therapy: report of two cases. Digest Liver Dis 2000;32(Suppl.2):A123.
17. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
18. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
19. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48-63
20. Truelove SC, Witts U. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041-8.
21. Prantera C, Lorenzetti R, Cerro P, Davoli M, Brancato G, Fanucci A. The plain abdominal film accurately estimates extent of active ulcerative colitis. J Clin Gastroenterol 1991;13:231-4.
22. Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporin for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995; 20:285-9.
23. Van Gossum A, Schmit A, Adler M, Chioccioli C, Fiasse R, Louwagie P et al. Short and long-tenri efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Acta Gastroenterol Belg 1997;60:197-200.
24. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic. The first 100 patients. Am J Gastroenterol 2001;96:729-32.
25. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry M, Rotter JI, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-55.
26. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102:1620-7.
27. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2 and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993;78:127-31.
28. Prantera C, Davoli M, Lorenzetti R. Clinical and laboratory indicators of extent of ulcerative colitis. J Clin Gastroenterol 1988;10:41-5.